Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor By Ogkologos - October 12, 2026 5 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the evERA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge Adjuvant fractionated radiotherapy significantly improves DFS in patients with atypical meningioma who have undergone complete surgical resection MOST POPULAR Having a Heart Attack May Make Breast Cancer Grow Faster August 17, 2020 21-Month-Old Girl Celebrates After Beating Stage 4 Cancer May 24, 2019 Second- or Third-Line Treatment with Tisotumab Vedotin Results in Greater Efficacy... July 12, 2024 ESMO Breast Cancer Congress 2023 April 17, 2023 Load more HOT NEWS Population-based lung cancer screening can reduce mortality in people who have... This Company Is Turning Scrap Wood Into 10,000+ Guitars For Sick... Study Finds Light Therapy Helps Radiation-Related Skin Damage Heal 50% Faster ΝΕΥΡΟΕΝΔΟΚΡΙΝΕΙΣ ΟΓΚΟΙ (ΝΕΤS)
